Does docetaxel prolong survival of patients with non-metastatic castration-resistant prostate cancer?

被引：15

作者：

Ito, Kagenori ^{[1
]}

Kimura, Takahiro ^{[1
]}

Onuma, Hajime ^{[1
]}

Tabata, Ryuji ^{[1
]}

Shimomura, Tatsuya ^{[1
]}

Miki, Kenta ^{[1
]}

Tomita, Masayuki ^{[1
]}

Egawa, Shin ^{[1
]}

机构：

[1] Jikei Univ, Dept Urol, Sch Med, Tokyo, Japan

来源：

PROSTATE | 2018年 / 78卷 / 07期

关键词：

PHASE-II; THERAPY; TRIAL; MITOXANTRONE; PREDNISONE; ANTIGEN; JAPAN;

D O I：

10.1002/pros.23493

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

BackgroundGuidelines define docetaxel as a first-line therapeutic option for metastatic castration-resistant prostate cancer (mCRPC). However, the role of docetaxel in non-metastatic castration-resistant prostate cancer (nmCRPC) has not been fully investigated. The aim of this retrospective study was to evaluate the potential role of docetaxel in nmCRPC. Clinical outcomes including overall survival were compared between CRPC patients who had docetaxel introduced while in nonmetastatic versus metastatic diseases. MethodsA total of 98 CRPC patients had docetaxel therapy. Of these 46 patients received docetaxel for nmCRPC, and 52 had distant metastases. Clinical outcomes from the time of diagnosis of CRPC were compared retrospectively between groups. ResultsThe median observation period after the diagnosis of CRPC in these patients was 42 months (range, 3-166). Overall survival (OS) was significantly longer in the nmCRPC group than in the mCRPC group (not reached vs 52.2 months, respectively, P=0.006). Multivariate analysis showed that longer time to CRPC, docetaxel use in nmCRPC, and use of abiraterone acetate and/or enzalutamide were significant predictors for improved OS (P=0.04, 0.019 and 0.002, respectively). The incidence and profile of adverse events did not differ significantly between groups. ConclusionsEarlier induction of docetaxel in nmCRPC patients may prolong OS. Further prospective studies in more patients will be required to confirm our findings.

引用

页码：498 / 505

页数：8

共 23 条

[1] Characteristics of patients with prostate cancer who have initially been treated by hormone therapy in Japan: J-CaP surveillance [J].

Akaza, H ;

Usami, M ;

Hinotsu, S ;

Ogawa, O ;

Kagawa, S ;

Kitamura, T ;

Tsukamoto, T ;

Naito, S ;

Hirao, Y ;

Murai, M ;

Yamanaka, H .

JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2004, 34 (06) :329-336

[2]

[Anonymous], 2016, PROJ CANC STAT

[3] Treatment of mCRPC in the AR-axis-targeted therapy-resistant state [J].

Chi, K. ;

Hotte, S. J. ;

Joshua, A. M. ;

North, S. ;

Wyatt, A. W. ;

Collins, L. L. ;

Saad, F. .

ANNALS OF ONCOLOGY, 2015, 26 (10) :2044-2056

[4] New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].

Eisenhauer, E. A. ;

Therasse, P. ;

Bogaerts, J. ;

Schwartz, L. H. ;

Sargent, D. ;

Ford, R. ;

Dancey, J. ;

Arbuck, S. ;

Gwyther, S. ;

Mooney, M. ;

Rubinstein, L. ;

Shankar, L. ;

Dodd, L. ;

Kaplan, R. ;

Lacombe, D. ;

Verweij, J. .

EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247

[5] Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer [J].

Fizazi, Karim ;

NamPhuong Tran ;

Fein, Luis ;

Matsubara, Nobuaki ;

Rodriguez-Antolin, Alfredo ;

Alekseev, Boris Y. ;

Ozguroglu, Mustafa ;

Ye, Dingwei ;

Feyerabend, Susan ;

Protheroe, Andrew ;

De Porre, Peter ;

Kheoh, Thian ;

Park, Youn C. ;

Todd, Mary B. ;

Chi, Kim N. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (04) :352-360

[6] Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial [J].

Gravis, Gwenaelle ;

Fizazi, Karim ;

Joly, Florence ;

Oudard, Stephane ;

Priou, Franck ;

Esterni, Benjamin ;

Latorzeff, Igor ;

Delva, Remy ;

Krakowski, Ivan ;

Laguerre, Brigitte ;

Rolland, Frederic ;

Theodore, Christine ;

Deplanque, Gael ;

Ferrero, Jean Marc ;

Pouessel, Damien ;

Mourey, Loic ;

Beuzeboc, Philippe ;

Zanetta, Sylvie ;

Habibian, Muriel ;

Berdah, Jean Francois ;

Dauba, Jerome ;

Baciuchka, Marjorie ;

Platini, Christian ;

Linassier, Claude ;

Labourey, Jean Luc ;

Machiels, Jean Pascal ;

El Kouri, Claude ;

Ravaud, Alain ;

Suc, Etienne ;

Eymard, Jean Christophe ;

Hasbini, Ali ;

Bousquet, Guilhem ;

Soulie, Michel .

LANCET ONCOLOGY, 2013, 14 (02) :149-158

[7] Phase II Study of Single-Agent Orteronel (TAK-700) in Patients with Nonmetastatic Castration-Resistant Prostate Cancer and Rising Prostate-Specific Antigen [J].

Hussain, Maha ;

Corn, Paul G. ;

Michaelson, M. Dror ;

Hammers, Hans J. ;

Alumkal, Joshi J. ;

Ryan, Charles J. ;

Bruce, Justine Y. ;

Moran, Susan ;

Lee, Shih-Yuan ;

Lin, H. Mark ;

George, Daniel J. .

CLINICAL CANCER RESEARCH, 2014, 20 (16) :4218-4227

[8]

International Agency for Research on Cancer, 2012, PROST CANC EST INC M

[9] Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy [J].

James, N. D. ;

de Bono, J. S. ;

Spears, M. R. ;

Clarke, N. W. ;

Mason, M. D. ;

Dearnaley, D. P. ;

Ritchie, A. W. S. ;

Amos, C. L. ;

Gilson, C. ;

Jones, R. J. ;

Matheson, D. ;

Miliman, R. ;

Attard, G. ;

Chowdhury, S. ;

Cross, W. R. ;

Gillessen, S. ;

Parker, C. C. ;

Russell, J. M. ;

Berthold, D. R. ;

Brawley, C. ;

Adab, F. ;

Aung, S. ;

Birtle, A. J. ;

Bowen, J. ;

Brock, S. ;

Chakraborti, P. ;

Ferguson, C. ;

Gale, J. ;

Gray, E. ;

Hingorani, M. ;

Hoskin, P. J. ;

Lester, J. F. ;

Malik, Z. I. ;

McKinna, F. ;

McPhail, N. ;

Money-Kyrle, J. ;

O'Sullivan, J. ;

Parikh, O. ;

Protheroe, A. ;

Robinson, A. ;

Srihari, N. N. ;

Thomas, C. ;

Wagstaff, J. ;

Wylie, J. ;

Zarkar, A. ;

Parmar, M. K. B. ;

Sydes, M. R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (04) :338-351

[10] Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial [J].

James, Nicholas D. ;

Sydes, Matthew R. ;

Clarke, Noel W. ;

Mason, Malcolm D. ;

Dearnaley, David P. ;

Spears, Melissa R. ;

Ritchie, Alastair W. S. ;

Parker, Christopher C. ;

Russell, J. Martin ;

Attard, Gerhardt ;

de Bono, Johann ;

Cross, William ;

Jones, Rob J. ;

Thalmann, George ;

Amos, Claire ;

Matheson, David ;

Millman, Robin ;

Alzouebi, Mymoona ;

Beesley, Sharon ;

Birtle, Alison J. ;

Brock, Susannah ;

Cathomas, Richard ;

Chakraborti, Prabir ;

Chowdhury, Simon ;

Cook, Audrey ;

Elliott, Tony ;

Gale, Joanna ;

Gibbs, Stephanie ;

Graham, John D. ;

Hetherington, John ;

Hughes, Robert ;

Laing, Robert ;

McKinna, Fiona ;

McLaren, Duncan B. ;

O'Sullivan, Joe M. ;

Parikh, Omi ;

Peedell, Clive ;

Protheroe, Andrew ;

Robinson, Angus J. ;

Srihari, Narayanan ;

Srinivasan, Rajaguru ;

Staffurth, John ;

Sundar, Santhanam ;

Tolan, Shaun ;

Tsang, David ;

Wagstaff, John ;

Parmar, Mahesh K. B. .

LANCET, 2016, 387 (10024) :1163-1177

← 1 2 3 →